Hospital Universitario Vall d'Hebron

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm	Active, not recruiting	Phase 2	2026-03-27		NCT02682641

Clinical trials